$IMRN Skyrockets 727% After NMRC Requests Meeting with FDA Regarding Phase 2 Clinical Trials for New Treatment of Diarrheal Infections

#nasdaq #stocks #stockmarket #investing #cnbc #foxbusiness #trading #tradeideas #daytrading #news

https://t.co/YBUYXAd3TP